THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM;THE TEXAS A&M UNIVERSITY SYSTEM;PULMOTECT, INC.
发明人:
DICKEY, BURTON F.,TUVIM, MICHAEL J.,EVANS, SCOTT E.,HOOK, MAGNUS,HUSTON, DAVID P.,MARTINEZ-MOCZYGEMBA, MARGARITA,SCOTT, BRENTON
申请号：
CA3043480
公开号：
CA3043480A1
申请日:
2017.11.09
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist / PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.
